Galectin Therapeutics Inc. (GALT)

[Darwinian]

Nash only?

I guessing that it's pretty likely that GR-MD-02 will also work for early stage cirrhotics whose disease was brought about by alcohol abuse. Pre-clinical work on rodents was on chemically induced liver disease. Alcohol abuse is (I think) still the leading cause of cirrhosis, followed closely by NASH. If that's the case—and it wouldn't be too hard to prove—the market is at least double for this drug.

Don't know if that would enter into any negotiations with partners or not...